SEMAGLUTIDE | N218316 | NOVO NORDISK INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2023-00722 | 8536122 | IPR | Mylan Pharmaceuticals Inc. et al. | Institution Denied | 2023-03-16 | 2023-10-02 |
| IPR2023-00723 | 8129343 | IPR | Mylan Pharmaceuticals Inc. et al. | Institution Denied | 2023-03-16 | 2023-10-02 |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2026-06-04 | Terminated 2026-06-12 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Code | Date | Status |
|---|---|---|
| I-935 | Mar 8, 2027 | < 1 year |
| NP | Dec 22, 2028 | Active |
Novo Nordisk added U.S. Patent No. 11,033,499 to the Orange Book listing for Wegovy (semaglutide) NDA 218316.
New: New record
Novo Nordisk added U.S. Patent 11,033,499 to the Orange Book listing for Wegovy (semaglutide) NDA 218316.
New: New record
Novo added U.S. Patent 11,033,499 to the Orange Book for semaglutide (Wegovy, NDA 218316).
New: New record
Novo Nordisk added U.S. Patent 11,033,499 to the Orange Book for Wegovy (semaglutide).
New: New record